Your browser doesn't support javascript.
loading
Letter to the Editor regarding 'Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study' by Moik F, Riedl JM, and Ay C.
Passaro, A; Wang, J; Shah, S; Bauml, J M; Campelo, R G; Cho, B C.
Afiliação
  • Passaro A; Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy. Electronic address: antonio.passaro@ieo.it.
  • Wang J; Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Shah S; Janssen Research & Development, Spring House, USA.
  • Bauml JM; Janssen Research & Development, Spring House, USA.
  • Campelo RG; University Hospital A Coruña, A Coruña, Spain.
  • Cho BC; Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
Ann Oncol ; 35(3): 328-329, 2024 Mar.
Article em En | MEDLINE | ID: mdl-38029840
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazóis / Pirimidinas / Acrilamidas / Morfolinas / Anticorpos Biespecíficos / Carcinoma Pulmonar de Células não Pequenas / Indóis / Neoplasias Pulmonares Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazóis / Pirimidinas / Acrilamidas / Morfolinas / Anticorpos Biespecíficos / Carcinoma Pulmonar de Células não Pequenas / Indóis / Neoplasias Pulmonares Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article